BR0310026A - Uso de docetaxel/doxorrubicina/ciclofosfamida em terapia adjuvante de câncer de mama e ovariano - Google Patents
Uso de docetaxel/doxorrubicina/ciclofosfamida em terapia adjuvante de câncer de mama e ovarianoInfo
- Publication number
- BR0310026A BR0310026A BR0310026-0A BR0310026A BR0310026A BR 0310026 A BR0310026 A BR 0310026A BR 0310026 A BR0310026 A BR 0310026A BR 0310026 A BR0310026 A BR 0310026A
- Authority
- BR
- Brazil
- Prior art keywords
- docetaxel
- breast
- cyclophosphamide
- doxorubicin
- ovarian cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"USO DE DOCETAXEL/DOXORRUBICINA/CICLOFOSFAMIDA EM TERAPIA ADJUVANTE DE CâNCER DE MAMA E OVARIANO". A presente invenção refere-se a um novo método de terapia adjuvante no tratamento de câncer de mama metastático ou ovariano, método este que compreende administrar seis ciclos de docetaxel, doxorrubicina e ciclofosfamida a um paciente em necessidade desse tratamento, no qual essas dosagens têm um efeito terapêutico marcado quando comparadas a outras terapias adjuvantes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38085002P | 2002-05-17 | 2002-05-17 | |
PCT/EP2003/007443 WO2003097164A1 (en) | 2002-05-17 | 2003-05-15 | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0310026A true BR0310026A (pt) | 2005-02-15 |
Family
ID=29550025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0310026-0A BR0310026A (pt) | 2002-05-17 | 2003-05-15 | Uso de docetaxel/doxorrubicina/ciclofosfamida em terapia adjuvante de câncer de mama e ovariano |
Country Status (28)
Country | Link |
---|---|
US (2) | US20040014694A1 (pt) |
EP (1) | EP1507573A1 (pt) |
JP (1) | JP4773719B2 (pt) |
KR (1) | KR20050000544A (pt) |
CN (1) | CN1652845A (pt) |
AU (1) | AU2003244646B2 (pt) |
BR (1) | BR0310026A (pt) |
CA (1) | CA2486124A1 (pt) |
CR (1) | CR7575A (pt) |
EC (1) | ECSP045433A (pt) |
HR (1) | HRPK20041072B3 (pt) |
IL (1) | IL165214A0 (pt) |
MA (1) | MA27417A1 (pt) |
ME (2) | ME00055B (pt) |
MX (1) | MXPA04010640A (pt) |
MY (1) | MY146533A (pt) |
NO (1) | NO20045370L (pt) |
NZ (1) | NZ535992A (pt) |
OA (1) | OA12819A (pt) |
PA (1) | PA8574001A1 (pt) |
RS (1) | RS96304A (pt) |
RU (1) | RU2321396C2 (pt) |
TN (1) | TNSN04217A1 (pt) |
TW (1) | TWI374741B (pt) |
UA (1) | UA81628C2 (pt) |
UY (1) | UY27812A1 (pt) |
WO (1) | WO2003097164A1 (pt) |
ZA (1) | ZA200408549B (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4779971B2 (ja) * | 2003-09-25 | 2011-09-28 | アステラス製薬株式会社 | ヒストンデアセチラーゼ阻害剤とトポイソメラーゼii阻害剤とからなる抗腫瘍剤 |
GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
WO2008027988A2 (en) * | 2006-08-31 | 2008-03-06 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation |
DK2694056T3 (da) * | 2011-04-01 | 2020-01-02 | Astrazeneca Ab | Terapeutisk behandling |
MY175800A (en) | 2011-11-30 | 2020-07-09 | Astrazeneca Ab | Combination treatment of cancer |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
US20160067182A1 (en) * | 2013-04-09 | 2016-03-10 | Merrimack Pharmaceuticals, Inc. | Methods and compositions for improving outcomes of liposomal chemotherapy |
WO2015164665A1 (en) | 2014-04-25 | 2015-10-29 | Genentech, Inc. | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
WO2016005962A2 (en) | 2014-07-11 | 2016-01-14 | Dr. Reddy’S Laboratories Limited | Stable liquid formulations of cyclophosphamide and processes |
US10849916B2 (en) | 2014-07-11 | 2020-12-01 | Dr. Reddys Laboratories Limited | Stable liquid formulations of cyclophosphamide and its impurities |
US10238650B2 (en) | 2015-03-06 | 2019-03-26 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
WO2017011399A1 (en) | 2015-07-13 | 2017-01-19 | Beyondspring Pharmaceuticals, Inc | Plinabulin compositions |
US20190054019A1 (en) * | 2015-10-22 | 2019-02-21 | Universidade De Santiago De Compostela | Methods for using regulators for increasing the expression or activation of p53 and/or regulators for reducing or inhibiting the expression of p63-alpha, for the treatment of non-alcoholic fatty liver disease (nafld) and/or non-alcoholic steatohepatitis (nash) |
IL260933B2 (en) | 2016-02-08 | 2023-04-01 | Beyondspring Pharmaceuticals Inc | Preparations containing tocorsol or its analogues |
US20190177430A1 (en) * | 2016-08-24 | 2019-06-13 | The Wistar Institute Of Anatomy And Biology | Methods of Treating Cancers With Chemotherapy With Reduced Toxicity |
WO2018067575A1 (en) * | 2016-10-03 | 2018-04-12 | Indiana University Research And Technology Corporation | Combination drug therapy reduces parp-1 related dna repair and increases the efficacy of genotoxic agents |
CN110431135A (zh) | 2017-01-06 | 2019-11-08 | 大连万春布林医药有限公司 | 微管蛋白结合化合物及其治疗用途 |
CA3052190A1 (en) * | 2017-02-01 | 2018-08-09 | Beyondspring Pharmaceuticals, Inc. | Method of reducing neutropenia |
US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
BR112020014960A2 (pt) | 2018-01-24 | 2020-12-22 | Beyondspring Pharmaceuticals, Inc. | Composição e método para redução de trombocitopenia |
JP7373170B2 (ja) | 2018-06-22 | 2023-11-02 | オハイオ ステート イノベーション ファウンデーション | ジヒドロオロト酸デヒドロゲナーゼ阻害のための方法及び組成物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601675B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
MX9102128A (es) | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US6441026B1 (en) * | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
US5565478A (en) * | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
US6262054B1 (en) * | 1996-02-01 | 2001-07-17 | Sloan-Kettering Institute Of Cancer Research | Combination therapy method for treating breast cancer using edatrexate |
US6323205B1 (en) * | 1996-07-17 | 2001-11-27 | Sloan-Kettering Institute For Cancer Research | Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors |
US6541508B2 (en) * | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
US20020128228A1 (en) * | 2000-12-01 | 2002-09-12 | Wen-Jen Hwu | Compositions and methods for the treatment of cancer |
-
2003
- 2003-05-15 CN CNA038112388A patent/CN1652845A/zh active Pending
- 2003-05-15 ME MEP-2008-163A patent/ME00055B/me unknown
- 2003-05-15 UA UA20041210381A patent/UA81628C2/uk unknown
- 2003-05-15 IL IL16521403A patent/IL165214A0/xx unknown
- 2003-05-15 ME MEP-163/08A patent/MEP16308A/xx unknown
- 2003-05-15 RS YU96304A patent/RS96304A/sr unknown
- 2003-05-15 AU AU2003244646A patent/AU2003244646B2/en not_active Ceased
- 2003-05-15 KR KR10-2004-7018431A patent/KR20050000544A/ko not_active Application Discontinuation
- 2003-05-15 RU RU2004136984/15A patent/RU2321396C2/ru not_active IP Right Cessation
- 2003-05-15 CA CA002486124A patent/CA2486124A1/en not_active Abandoned
- 2003-05-15 MX MXPA04010640A patent/MXPA04010640A/es active IP Right Grant
- 2003-05-15 WO PCT/EP2003/007443 patent/WO2003097164A1/en active Application Filing
- 2003-05-15 EP EP03738122A patent/EP1507573A1/en not_active Withdrawn
- 2003-05-15 NZ NZ535992A patent/NZ535992A/en not_active IP Right Cessation
- 2003-05-15 JP JP2004505157A patent/JP4773719B2/ja not_active Expired - Fee Related
- 2003-05-15 OA OA1200400307A patent/OA12819A/en unknown
- 2003-05-15 BR BR0310026-0A patent/BR0310026A/pt not_active IP Right Cessation
- 2003-05-16 US US10/439,827 patent/US20040014694A1/en not_active Abandoned
- 2003-05-16 MY MYPI20031829A patent/MY146533A/en unknown
- 2003-05-16 UY UY27812A patent/UY27812A1/es not_active Application Discontinuation
- 2003-05-16 PA PA20038574001A patent/PA8574001A1/es unknown
- 2003-05-16 TW TW092113275A patent/TWI374741B/zh not_active IP Right Cessation
-
2004
- 2004-10-21 ZA ZA2004/08549A patent/ZA200408549B/en unknown
- 2004-11-03 MA MA27924A patent/MA27417A1/fr unknown
- 2004-11-11 TN TNP2004000217A patent/TNSN04217A1/en unknown
- 2004-11-16 EC EC2004005433A patent/ECSP045433A/es unknown
- 2004-11-16 HR HR20041072A patent/HRPK20041072B3/xx not_active IP Right Cessation
- 2004-11-17 CR CR7575A patent/CR7575A/es unknown
- 2004-12-08 NO NO20045370A patent/NO20045370L/no not_active Application Discontinuation
-
2007
- 2007-06-28 US US11/769,859 patent/US20070265213A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ZA200408549B (en) | 2006-01-25 |
HRPK20041072B3 (en) | 2007-07-31 |
MA27417A1 (fr) | 2005-07-01 |
AU2003244646B2 (en) | 2008-08-07 |
TWI374741B (en) | 2012-10-21 |
US20070265213A1 (en) | 2007-11-15 |
PA8574001A1 (es) | 2003-12-19 |
WO2003097164A1 (en) | 2003-11-27 |
NO20045370L (no) | 2004-12-08 |
UA81628C2 (uk) | 2008-01-25 |
ME00055B (me) | 2010-10-10 |
RU2004136984A (ru) | 2005-06-27 |
MY146533A (en) | 2012-08-15 |
OA12819A (en) | 2006-07-10 |
IL165214A0 (en) | 2005-12-18 |
EP1507573A1 (en) | 2005-02-23 |
KR20050000544A (ko) | 2005-01-05 |
CA2486124A1 (en) | 2003-11-27 |
RU2321396C2 (ru) | 2008-04-10 |
ECSP045433A (es) | 2005-01-03 |
TNSN04217A1 (en) | 2007-03-12 |
JP4773719B2 (ja) | 2011-09-14 |
RS96304A (en) | 2006-10-27 |
MXPA04010640A (es) | 2005-08-16 |
UY27812A1 (es) | 2003-11-28 |
CR7575A (es) | 2006-05-10 |
JP2005529925A (ja) | 2005-10-06 |
CN1652845A (zh) | 2005-08-10 |
HRP20041072A2 (en) | 2005-06-30 |
MEP16308A (en) | 2010-06-10 |
NZ535992A (en) | 2008-11-28 |
TW200407152A (en) | 2004-05-16 |
US20040014694A1 (en) | 2004-01-22 |
AU2003244646A1 (en) | 2003-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0310026A (pt) | Uso de docetaxel/doxorrubicina/ciclofosfamida em terapia adjuvante de câncer de mama e ovariano | |
BR9906581A (pt) | Processo para administração de taxano encapsulado em lipossomos | |
BR0009647A (pt) | Docetaxel em combinação com rhumab her2 para o tratamento de cânceres | |
BRPI0509139A (pt) | composição, e, método de estimulação de uma resposta imune em um indivìduo, de tratamento profilático de uma doença, de melhoramento de um sinal ou sintoma associado com uma doença, de alvejamento de um tumor, de inibição do crescimento de tumor, e de detecção de um tumor | |
BR0213424A (pt) | Uso aperfeiçoado de composto antitumoral na terapia contra câncer | |
PT1187629E (pt) | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador | |
PA8479201A1 (es) | Derivados del acido hidroxi-pipecolato hidroxamico | |
BRPI0517976A (pt) | métodos de tratamento | |
BR0207487A (pt) | Método de tratamento de tumores em mamìferos e uso de compostos de epotilona | |
BR0209129A (pt) | Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos | |
NO20032027L (no) | Effektive antitumorbehandlinger | |
AR042051A1 (es) | Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer | |
BRPI0518250A2 (pt) | tratamentos anticÂncer | |
BR0209128A (pt) | Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos | |
MX2009003532A (es) | Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina. | |
TR200905706T1 (tr) | Pegile edilmiş lipozomal doksorubisinin uygulanması için usul | |
MX2007006927A (es) | Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer. | |
BR0113552A (pt) | Lipossomas que encapsulam fármacos anticancerìgenos e uso dos mesmos no tratamento de tumores malignos | |
DE60222383D1 (de) | Medikament zur verabreichung von amifostin und verwandten wirkstoffen | |
BR0111545A (pt) | Produto combinado, método para a produção de um kit de partes, kit de partes, método de tratamento de uma condição, usos de um produto combinado ou de um kit de partes, e, de um melagatrano e de um inibidor de fator xa, ou de um derivado farmaceuticamente aceitável dos mesmos | |
BR0114389A (pt) | Terapia antitumor que inclui derivado de distamicina | |
NZ528164A (en) | Use of flumazenil to produce a medicament for the treatment of cocaine dependency | |
BR0214564A (pt) | Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos | |
ATE233745T1 (de) | Arzneistoffe | |
MXPA03006359A (es) | Metodo para tratamiento del cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |
Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/337 (2006.01), A61P 35/00 (2006.01), A61K |